EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Platelet lipidomics indicates enhanced thrombocyte activation in patients with antiphospholipid syndrome in vivo

Susanne Heimerl, Marcus Höring, Ralph Burkhardt, Matthias Höpting, Alexander Sigruener, Gerhard Liebisch, Christina Hart

Journal of Thrombosis and Haemostasis · 2025-05 · 23 (5) · 1689-1697

DOI: 10.1016/j.jtha.2025.01.020 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Thrombosis and Haemostasis, 2025-05. Verfasst von Susanne Heimerl und 6 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany. Hauptthemen laut MEDLINE: Antiphospholipid Syndrome, Lipidomics, Blood Platelets, Platelet Activation. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Deutsche Forschungsgemeinschaft.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Antiphospholipid syndrome (APS) is an autoimmune disorder characterized by the presence of antiphospholipid antibodies in patients with thromboembolic/thromboinflammatory events and/or obstetric complications. OBJECTIVES: The aim of this study was to examine whether there are alterations in the platelet lipidome of APS patients in comparison with patients affected by thromboembolism without APS (control) and healthy volunteers. METHODS: We applied quantitative mass spectrometry-based lipidomics to investigate the platelet lipidome of isolated resting and thrombin-stimulated platelets as well as platelet release in patients with APS, controls, and healthy volunteers. RESULTS: Lipidomic data revealed an increase in lysophospholipids (LPLs) in platelets from APS patients, specifically in lysophosphatidylcholine and lysophosphatidylethanolamine species. As LPLs are cleavage products generated by phospholipase A (PLA) from the corresponding phospholipid precursor, LPL/phospholipid ratios may be employed as surrogates for PLA1 and PLA2 activities. The surrogate ratios for PLA2, which participates in the release of arachidonic acid during platelet activation, were significantly increased in APS in both resting platelets and upon thrombin-induced activation for phosphatidylcholine and phosphatidylethanolamine. The phosphatidylcholine-PLA2 surrogate ratio was found to correlate with serum levels of anti-β2-glycoprotein I and anticardiolipin immunoglobulin G. Finally, receiver operator characteristic analysis demonstrated excellent discrimination of patients with APS from controls and healthy volunteers. CONCLUSION: These findings provide substantial evidence that platelet activation is enhanced in APS in vivo, involving the activation of PLA2.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antiphospholipid SyndromeLipidomicsBlood PlateletsPlatelet ActivationHumansFemaleAdultMiddle AgedCase-Control StudiesLysophospholipidsMaleAntibodies, AntiphospholipidPhospholipases A2ThrombinThromboembolismbeta 2-Glycoprotein IBiomarkersAntibodies, AnticardiolipinPhosphatidylethanolaminesLysophosphatidylcholines

Stichwörter der Autor:innen

antiphospholipid syndromeblood plateletslipidomicsplatelet activationplatelet function tests

Substanzen

LysophospholipidsAntibodies, AntiphospholipidlysophosphatidylethanolaminePhospholipases A2Thrombinbeta 2-Glycoprotein IBiomarkersAntibodies, AnticardiolipinPhosphatidylethanolaminesLysophosphatidylcholines

Autor:innen und Institutionen

  • Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany.
  • Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany.
  • Institute of Clinical Chemistry and Laboratory Medicine, University Hospital Regensburg, Regensburg, Germany. Electronic address: gerhard.liebisch@ukr.de.
  • Department of Hematology and Oncology, Internal Medicine III, University Hospital Regensburg, Regensburg, Germany. Electronic address: christina.hart@ukr.de.

Förderung

  • Deutsche Forschungsgemeinschaft

Zitieren

APA

Heimerl, S., Höring, M., Burkhardt, R., Höpting, M., Sigruener, A., Liebisch, G., & Hart, C. (2025). Platelet lipidomics indicates enhanced thrombocyte activation in patients with antiphospholipid syndrome in vivo. Journal of Thrombosis and Haemostasis, 23(5), 1689-1697. https://doi.org/10.1016/j.jtha.2025.01.020

Vancouver

Heimerl S, Höring M, Burkhardt R, Höpting M, Sigruener A, Liebisch G, et al. Platelet lipidomics indicates enhanced thrombocyte activation in patients with antiphospholipid syndrome in vivo. Journal of Thrombosis and Haemostasis. 2025;23(5):1689-1697. doi:10.1016/j.jtha.2025.01.020

BibTeX
@article{Heimerl2025,
  author = {Heimerl, Susanne and Höring, Marcus and Burkhardt, Ralph and Höpting, Matthias and Sigruener, Alexander and Liebisch, Gerhard and Hart, Christina},
  title = {Platelet lipidomics indicates enhanced thrombocyte activation in patients with antiphospholipid syndrome in vivo},
  journal = {Journal of Thrombosis and Haemostasis},
  year = {2025},
  volume = {23},
  number = {5},
  pages = {1689--1697},
  doi = {10.1016/j.jtha.2025.01.020}
}
Kostenlos starten →